Name | SW-100 |
---|
Description | SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier[1]. |
---|---|
Related Catalog | |
Target |
HDAC1:5.23 μM (IC50) HDAC2:32.8 μM (IC50) HDAC3:29.5 μM (IC50) HDAC4:10.9 μM (IC50) HDAC5:4.07 μM (IC50) HDAC6:2.3 nM (IC50) HDAC7:4.55 μM (IC50) HDAC8:3.72 μM (IC50) HDAC9:3.46 μM (IC50) HDAC10:26.2 μM (IC50) HDAC11:5.72 μM (IC50) |
In Vitro | SW-100 (0.01-10 µM; 48 hours) shows obvious increase in the acetylated α-tubulin levels in a dose-dependent manner[1]. Western Blot Analysis[1] Cell Line: HEK293 cells Concentration: 0.01, 0.1, 1, 10 µM Incubation Time: 48 hours Result: Showed obvious increase in the acetylated α-tubulin levels in a dose-dependent manner. |
In Vivo | SW-100 (20 mg/kg; i.p.; twice a day for two days) ameliorates several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in mouse model of Fragile X syndrome[1]. Animal Model: 8-10 weeks old C57BL/6 mice (Fmr1-/- mice)[1] Dosage: 20 mg/kg Administration: Intraperitoneal injection; twice a day for two days Result: Ameliorated several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in Fmr1-/- mice。 |
References |
Molecular Formula | C17H17ClN2O2 |
---|---|
Molecular Weight | 316.78 |
Storage condition | 2-8℃ |